The role of the IL-33/ST2 axis in autoimmune disorders: Friend or foe?. (December 2019)

• Record Type: Journal Article
• Authors: Liu, Xiuxing; Xiao, Yichen; Pan, Yuan; Li, He; Zheng, Song Guo; Su, Wenru
• Is Part Of: Cytokine & growth factor reviews. Volume 50(2019)
• Page Start: 60
• Page End: 74
• Publication Date: 2019-12
• Subjects: ADs autoimmune diseases -- Th T effector -- IL-33 interleukin-33 -- HEV high endothelial venules -- ECs endothelial cells -- DCs dendritic cells -- ST2 suppression of tumorigenicity 2 -- MCs mast cells -- ILC2s group 2 innate lymphoid cells -- CNS central nervous system -- IBDs inflammatory bowel diseases -- RA rheumatoid arthritis -- MS multiple sclerosis -- SSc systemic sclerosis -- SLE systemic lupus erythematosus -- T1D type 1 diabetes -- IFIL-33 full-length IL-33 -- TF transcription factor -- NF-κB nuclear factor kappaB -- TNF tumor necrosis factor -- HC healthy control -- TLRs toll-like receptors -- TGF-β transforming growth factor-β -- IFN interferon -- TIR toll-like receptor/IL-1 receptor -- IL-1RAcP IL-1 receptor accessory protein -- MyD88 myeloid differentiation factor 88 -- IRAK IL-1R-associated kinase -- TRAF6 TNF receptor-associated factor 6 -- AP-1 activator protein-1 -- ERK extracellular signal-regulated kinase -- p38MAPK p38 mitogen-associated protein kinase -- JNK c-Jun N-terminal kinase -- TIR toll/IL-1 receptor -- SIGIRR single Ig IL-1R-related molecule -- ECM extracellular matrix -- M2 macrophage the alternatively activated macrophage -- Tregs regulatory T cells -- SF synovial fluid -- CRP C-reactive protein -- ESR erythrocyte sedimentation rate -- CIA collagen-induced arthritis -- WT wild-type -- AIA autoantibody-induced arthritis -- HIF-1α hypoxia-inducible factor-1α -- UC ulcerative colitis -- CD Crohn's disease -- DSS dextran sodium sulfate -- CSF cerebrospinal fluid -- OPCs oligodendrocyte precursor cells -- EAE experimental autoimmune encephalomyelitis -- MDSCs myeloid-derived suppressor cells -- PKC protein kinase C -- I/R ischemia/reperfusion -- DKZ diacylglycerol kinase zeta -- PBMC peripheral blood mononuclear cell -- lcSSc limited cutaneous SSc -- PI3K phosphatidylinositide 3-kinases -- AKT protein kinase B -- eNOS endothelial nitric oxide synthase -- BD Behcet's disease -- RPE retinal pigment epithelial -- EAU experimental autoimmune uveitis -- AIHA autoimmune hemolytic anemia -- PBC primary biliary cirrhosis; Interleukin-33 -- Autoimmune diseases -- ST2 -- Th1 -- Th17 -- Type 2 immune responses; Cytokines -- Periodicals; 571.84
• DOI: 10.1016/j.cytogfr.2019.04.004
• Languages: English
• ISSNs: 1359-6101

Abstract

Graphical abstract: Highlights: IL-33 and its receptors have convincing clinical value for autoimmune diseases. IL-33/ST2 axis mainly plays a detrimental role in a wide range of autoimmune diseases, although it has anti-autoimmune bioeffects. IL-33/ST2 axis promotes autoimmune diseases by regulating the balance between Th1/Th17 cells and Tregs. IL-33/ST2-mediated type 2 immune responses are equally important for the regulation of disease development. Abstract: Autoimmune diseases (ADs), which are common immune-mediated inflammatory syndromes, are characterized by an imbalance between T effector (Th)1/Th17 cells and T regulatory cells. Interleukin (IL)-33, a member of the IL-1 family, induces inflammatory disease development by mediating type 2 immune responses. Recently, IL-33/ST2 axis was reported to induce autoimmunity involving Th1 and Th17 cells. In this review, we focus on the expression, regulation and function of IL-33/ST2 pathway in the context of autoimmune disorders. We discuss the clinical potential of this signaling pathway in predicting disease activity and severity and offer possible future therapeutic alternatives.